Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.

Trial Details

NCT ID
NCT05872347
Phase
PHASE2
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • SPH4336 Tablets
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Liuzhou, Guangxi, China|24.32405,109.40698
  • Anyang, He'nan, China|36.096,114.38278

Key Eligibility Criteria

  • Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF).
  • ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
  • Life expectancy ≥ 3 months.
  • Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →